In Vitro and in Silico Evaluation of Some New 1H-Benzimidazoles Bearing Thiosemicarbazide and Triazole as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

ÇELİK İ., Ayhan-Kilcigil G., GÜVEN B., Kara Z., Onay-Besikci A.

POLYCYCLIC AROMATIC COMPOUNDS, vol.43, no.1, pp.444-455, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 43 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.1080/10406638.2021.2015404
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, Applied Science & Technology Source, CAB Abstracts, Chemical Abstracts Core, Communication Abstracts, Food Science & Technology Abstracts, Metadex, Pollution Abstracts, Veterinary Science Database, Civil Engineering Abstracts
  • Page Numbers: pp.444-455
  • Keywords: Benzimidazole, bis-triazole, bis-thiosemicarbazide, EGFR inhibitor activity, molecular docking, MM-GBSA, BENZIMIDAZOLE, DERIVATIVES, ANTICANCER, DOCKING, DESIGN, CANCER
  • Erciyes University Affiliated: Yes


A new class of benzimidazole derivatives bearing bis-triazole or bis-thiosemicarbazide structure was designed and synthesized as potential inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. In vitro EGFR kinase enzyme inhibition properties were determined in comparison with erlotinib and compound (6b) containing propyl side chain at the 4th position of triazole rings showed 13.8% inhibition. Molecular docking studies were performed and docking score and binding energy were established. The most active compound formed a hydrogen bond between the Asn818 and triazole NH at the 2nd position of the benzimidazole skeleton. Predicted ADME profiles of the compounds were calculated and found to be within the appropriate reference ranges.